InsidersTradesSigma
Follow the 메타바이오메드 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has published 4 insider filings. Market capitalisation: €102.3bn. The latest transaction was filed on 27 April 2026 (Purchase). Among the most active insiders: 오지수. The full history is free.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Meta Biomed es una empresa que cotiza en el mercado XKRX, especializada en el sector de la salud y farmacéutico. Se enfoca en el desarrollo y la comercialización de soluciones innovadoras para el campo médico.